140 related articles for article (PubMed ID: 27510251)
41. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294
[TBL] [Abstract][Full Text] [Related]
42. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
He YJ; Zhang W; Chen Y; Guo D; Tu JH; Xu LY; Tan ZR; Chen BL; Li Z; Zhou G; Yu BN; Kirchheiner J; Zhou HH
Clin Chim Acta; 2009 Jul; 405(1-2):49-52. PubMed ID: 19374892
[TBL] [Abstract][Full Text] [Related]
43. Elevated Plasma Moxifloxacin Concentrations and
Weiner M; Gelfond J; Johnson-Pais TL; Engle M; Peloquin CA; Johnson JL; Sizemore EE; Mac Kenzie WR
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463526
[TBL] [Abstract][Full Text] [Related]
44. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
Clin Pharmacol Ther; 2011 Sep; 90(3):406-13. PubMed ID: 21814190
[TBL] [Abstract][Full Text] [Related]
45. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
Ni W; Ji J; Dai Z; Papp A; Johnson AJ; Ahn S; Farley KL; Lin TS; Dalton JT; Li X; Jarjoura D; Byrd JC; Sadee W; Grever MR; Phelps MA
PLoS One; 2010 Nov; 5(11):e13792. PubMed ID: 21072184
[TBL] [Abstract][Full Text] [Related]
46. Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis.
Le Doare K; Barber N; Doerholt K; Sharland M
BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23355589
[TBL] [Abstract][Full Text] [Related]
47. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
[TBL] [Abstract][Full Text] [Related]
48. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.
Francis J; Zvada SP; Denti P; Hatherill M; Charalambous S; Mungofa S; Dawson R; Dorman S; Gupte N; Wiesner L; Jindani A; Harrison TS; Olagunju A; Egan D; Owen A; McIlleron HM
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670438
[TBL] [Abstract][Full Text] [Related]
49. No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects.
Li M; Hu Y; Li H; Wen Z; Hu X; Zhang D; Zhang Y; Xiao J; Tang J; Chen X
Biol Pharm Bull; 2017; 40(1):88-96. PubMed ID: 28049954
[TBL] [Abstract][Full Text] [Related]
50. SLCO1B1 Gene Polymorphisms (rs2306283 and rs4149056) and Statin-Induced Myopathy in Jordanian Diabetics.
Shahrure ZM; Irshaid YM; Mustafa KN; Abujbara MA; Al Shhab M; El-Khateeb MS; Ajlouni KM
Curr Rev Clin Exp Pharmacol; 2021; 16(3):281-288. PubMed ID: 32860365
[TBL] [Abstract][Full Text] [Related]
51. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
Niemi M; Kivistö KT; Diczfalusy U; Bodin K; Bertilsson L; Fromm MF; Eichelbaum M
Pharmacogenet Genomics; 2006 Aug; 16(8):565-8. PubMed ID: 16847425
[TBL] [Abstract][Full Text] [Related]
52. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
[TBL] [Abstract][Full Text] [Related]
53. [Polymorphism of the biotransformation gene--cytochrome-450 2C9 in the patients with tuberculosis].
Antonenko PB; Kresyun VI
Mol Gen Mikrobiol Virusol; 2014; (3):18-22. PubMed ID: 25335408
[TBL] [Abstract][Full Text] [Related]
54. SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.
Sortica VA; Fiegenbaum M; Lima LO; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Chem Lab Med; 2012 Mar; 50(3):441-8. PubMed ID: 22505549
[TBL] [Abstract][Full Text] [Related]
55. N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis.
Hemanth Kumar AK; Ramesh K; Kannan T; Sudha V; Haribabu H; Lavanya J; Swaminathan S; Ramachandran G
Indian J Med Res; 2017 Jan; 145(1):118-123. PubMed ID: 28574024
[TBL] [Abstract][Full Text] [Related]
56. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
Aquilante CL; Bushman LR; Knutsen SD; Burt LE; Rome LC; Kosmiski LA
Hum Genomics; 2008 Sep; 3(1):7-16. PubMed ID: 19129086
[TBL] [Abstract][Full Text] [Related]
57. An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C.
Soko ND; Chimusa E; Masimirembwa C; Dandara C
Pharmacogenomics J; 2019 Jun; 19(3):240-248. PubMed ID: 30100615
[TBL] [Abstract][Full Text] [Related]
58. Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy.
Treenert A; Areepium N; Tanasanvimon S
Asian Pac J Cancer Prev; 2018 Oct; 19(10):2757-2764. PubMed ID: 30360603
[TBL] [Abstract][Full Text] [Related]
59. Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics.
Allegra S; Fatiguso G; Calcagno A; Baietto L; Motta I; Favata F; Cusato J; Bonora S; Di Perri G; D'Avolio A
Pharmacogenomics; 2017 Jun; 18(9):865-880. PubMed ID: 28594304
[TBL] [Abstract][Full Text] [Related]
60. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
